.png){kind=icon}
返回
Thyroid Cancer
.png){kind=icon}
PRE
AI
DOI：10.1001/jama.2023.26348.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Importance Approximately 43 720 new cases of thyroid carcinoma are expected to be diagnosed in 2023 in the US. Five-year relative survival is approximately 98.5%. This review summarizes current evidence regarding pathophysiology, diagnosis, and management of early-stage and advanced thyroid cancer. Observations Papillary thyroid cancer accounts for approximately 84% of all thyroid cancers. Papillary, follicular (approximate to 4%), and oncocytic (approximate to 2%) forms arise from thyroid follicular cells and are termed well-differentiated thyroid cancer. Aggressive forms of follicular cell-derived thyroid cancer are poorly differentiated thyroid cancer (approximate to 5%) and anaplastic thyroid cancer (approximate to 1%). Medullary thyroid cancer (approximate to 4%) arises from parafollicular C cells. Most cases of well-differentiated thyroid cancer are asymptomatic and detected during physical examination or incidentally found on diagnostic imaging studies. For microcarcinomas (<= 1 cm), observation without surgical resection can be considered. For tumors larger than 1 cm with or without lymph node metastases, surgery with or without radioactive iodine is curative in most cases. Surgical resection is the preferred approach for patients with recurrent locoregional disease. For metastatic disease, surgical resection or stereotactic body irradiation is favored over systemic therapy (eg, lenvatinib, dabrafenib). Antiangiogenic multikinase inhibitors (eg, sorafenib, lenvatinib, cabozantinib) are approved for thyroid cancer that does not respond to radioactive iodine, with response rates 12% to 65%. Targeted therapies such as dabrafenib and selpercatinib are directed to genetic mutations (BRAF, RET, NTRK, MEK) that give rise to thyroid cancer and are used in patients with advanced thyroid carcinoma. Conclusions Approximately 44 000 new cases of thyroid cancer are diagnosed each year in the US, with a 5-year relative survival of 98.5%. Surgery is curative in most cases of well-differentiated thyroid cancer. Radioactive iodine treatment after surgery improves overall survival in patients at high risk of recurrence. Antiangiogenic multikinase inhibitors and targeted therapies to genetic mutations that give rise to thyroid cancer are increasingly used in the treatment of metastatic disease.
Keyword:
ASSOCIATION GUIDELINES
RADIOACTIVE IODINE
DOUBLE-BLIND
FOLLOW-UP
GENOMIC CHARACTERIZATION
THYROTROPIN SUPPRESSION
MOLECULAR-GENETICS
TASK-FORCE
RADIOIODINE
CARCINOMA
期刊
J
IF:
55
论文数:
4.1W
被引数:
19.4W
机构
引用论文
分享收藏Reassessing surgical guidelines for papillary thyroid cancer impact on survival: Expanding indications for lobectomy.png)
SURGERY
OAAI
SURGERYIF2.7
OAAI分享收藏2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer2019欧洲甲状腺协会晚期放射性碘难治性甲状腺癌治疗和随访指南OAAI
OAAI分享收藏
查看更多内容